In the evolving landscape of clinical research, data privacy, compliance, and transparency are more critical than ever. Regulatory agencies around the world—such as the EMA, Health Canada, and the FDA—are demanding higher levels of transparency in clinical trial documentation while simultaneously holding sponsors accountable for protecting sensitive Confidential Information (CI), including trade secrets and intellectual property (IP).
This dual mandate has created a paradox for life sciences organizations: How can companies be transparent without compromising confidentiality and protection of its trade secrets and IP? The answer lies in technology—and more specifically, in RLS Protect Confidential Information Management (CIM), a groundbreaking platform developed by Real Life Sciences (RLS). CIM is redefining how pharmaceutical companies and contract research organizations (CROs) identify, review, approve, and manage confidential information across the clinical trial lifecycle.
The regulatory landscape surrounding clinical data disclosure has grown increasingly complex. Regulations such as EU Clinical Trial Regulation (CTR), EMA Policy 0070 and Health Canada’s Public Release of Clinical Information guidance require that sponsors disclose vast amounts of clinical data for public review. However, this disclosure must be executed with extreme caution—companies must carefully redact personal data, proprietary processes, compound names, and other CI that, if released, could harm competitive advantage or violate privacy laws such as GDPR.
Traditional redaction processes are manual, time-consuming, error-prone, and often lack cross-functional transparency. As documents pass between regulatory, legal, medical writing, and data privacy teams, the risk of inconsistency or misclassification increases—leading to compliance gaps, costly rework, or even worse - premature release of confidential information or public relations nightmares.
That’s where RLS Protect CIM comes in.
RLS Protect CIM is a web-based Software as a Service (SaaS) platform that provides pharmaceutical manufacturers with end-to-end management and visibility of confidential information . Designed specifically for clinical trials, CIM, in combination with RLS Protect for document redaction, is a centralized, collaborative system that enables teams to:
CIM transforms confidential information management from a reactive, manual process into a proactive, intelligent workflow supported by real-time collaboration and machine learning.
At its core, CIM helps sponsors protect what matters most— proprietary data, novel compounds, and strategic insights. By systematically managing CI through a structured workflow, sponsors reduce the risk of accidental disclosure of trade secrets, compound codes, or proprietary formulations.
With CIM, organizations can build a CI library tied to specific assets (such as investigational drugs or molecules), classify each CI by category, and define justifications for protection. This ensures CI is tracked consistently across projects and documents.
CIM doesn’t just manage known CI—it actively scans the public domain for potential matches, alerting stakeholders if confidential information appears to have been previously disclosed. This feature is invaluable for monitoring data leakage and responding quickly if proprietary data becomes public outside the approved process
CIM also integrates directly with RLS Protect Docs, allowing users to auto-load CI annotations into redaction workflows. This means that any CI flagged in CIM will automatically be suggested for redaction while preparing documents for publication—streamlining compliance and reducing human error.
CIM provides a full audit trail of every CI item, capturing who in the organization processed it, when it was reviewed or approved (and by whom), and any changes to its classification. This traceability is essential during regulatory audits and inspections and for standardizing and tracking confidential information internally in real time.
The system also enables different user roles—such as Admin, CIM Manager, Reviewer, and Approver—ensuring that only authorized individuals perform specific actions. Workflow statuses like “Draft,” “Submitted for Review,” “In Approval,” and “Approved” provide transparency into where each CI item stands in the review lifecycle.
This level of governance is not just best practice—it’s increasingly becoming the norm for organizations seeking to improve visibility and control around confidential information for their enterprise.
One of the biggest pain points in document disclosure and redaction projects is the seemingly endless back-and-forth between teams. Different departments have different definitions of what constitutes CI, leading to inconsistent decisions, delayed timelines, and frustration. These perspectives may or may not align to that of the Health Authority.
CIM solves this by centralizing CI decision-making. Once a CI is reviewed and approved within CIM, that decision is codified across the entire organization. Any redaction specialist, legal resource, or regulatory lead reviewing a document knows exactly what to redact—because the approved CI is already captured in the system..
Fewer meetings. Fewer errors. Faster submissions and document review cycles..
With clinical development pipelines expanding, legal requests multiplying and global submissions becoming the norm, sponsors must manage redaction efforts across hundreds of studies and thousands of documents. Manual systems simply don’t scale.
CIM is designed for scale. It allows users to link CI to specific projects, track National Clinical Trial (NCT) numbers and other registry identifiers, and provide real-time visibility to all pending and approvedt CI data across teams. New CI can also be added from within the fully integrated RLS Protect Docs module while redacting, ensuring nothing is missed—even in fast-paced, high-volume environments.
While traditional redaction is purely manual, CIM enhances automation through innovative and verified technologies like Natural Language Processing (NLP) and Machine Learning (ML). These features proactively identify likely CI candidates in documents based on trained models.
This intelligent layer adds speed and consistency while freeing up subject matter experts to focus on the most sensitive decisions.
CIM requires no local installation and is accessible via any supported web browser. Hosted and maintained by RLS, it includes technical support, routine updates, and minimal downtime thanks to off-hours release schedules. RLS maintains a robust Information Security Management System and ISO 27001 certificate to ensure your data is safe and secure at all times.
It also offers robust filtering, exporting, and role-based permission controls, allowing organizations to tailor usage to their structure, roles and responsibilities. Whether you’re a multinational pharma company or a nimble biotech, CIM is designed to adapt to your needs.
In today’s clinical trials regulatory environment, maintaining control over confidential information is no longer optional—it’s a critical success factor. Transparency and disclosure obligations will only increase, and companies that fail to manage CI effectively risk reputational damage, regulatory penalties, or worse: loss of competitive edge.
RLS Protect CIM empowers teams to face these challenges with confidence. It combines rigorous compliance with operational efficiency, helping sponsors safeguard their IP, streamline workflows, and meet global transparency requirements.
For any life sciences organization serious about disclosure readiness, consistency and protecting company IP, RLS Protect CIM is not just a tool—it’s a strategic imperative.
Don’t let confidentiality gaps delay your submissions or put your IP at risk. Contact Real Life Sciences today to learn how RLS Protect CIM ensures regulatory compliance—efficiently and at scale